Biomarker Analysis Services for Inflammatory Bowel Disease
Ace Therapeutics offers specialized biomarker analysis services exclusively focused on drug discovery and preclinical development for Inflammatory Bowel Disease (IBD). Our comprehensive biomarker panel is designed to facilitate a deep understanding of IBD pathophysiology, supporting the advancement of novel therapeutics. Please note that all services are strictly limited to preclinical research and drug development; we do not provide clinical diagnostic services.
Effective therapeutic intervention for IBD begins with robust biomarker discovery and identification. At Ace Therapeutics, our biomarker discovery services are integral to the early stages of drug development, enabling the identification of molecular indicators associated with disease mechanisms and therapeutic response. Our process involves high-throughput screening of candidate biomarkers, followed by rigorous validation using state-of-the-art analytical platforms. This systematic approach ensures the selection of biomarkers with the greatest potential to inform target engagement, efficacy, and safety in preclinical models.
Multi Omics: Our multi-omics approach leverages cutting-edge genomics, transcriptomics, proteomics, and metabolomics technologies to comprehensively investigate biological systems relevant to IBD. By integrating data across DNA, RNA, protein, and metabolite levels, we enable the identification of biomarkers reflecting key disease processes. This approach provides insights into immune regulation, inflammatory signaling, cytokine networks, and tissue remodeling pathways central to IBD pathogenesis. Our technologies support the elucidation of complex molecular interactions, facilitating the discovery of novel research targets for therapeutic development.
Candidate Validation: We employ rigorous validation strategies to establish the relevance of candidate biomarkers to IBD pathophysiology. This includes preliminary screening in relevant biological matrices, assessment of differential expression in disease versus control models, and correlation with known disease mechanisms. Candidates are prioritized based on criteria such as biological plausibility, reproducibility, and association with disease activity or therapeutic response. Our methodology ensures that only the most promising research biomarkers are advanced for further assay development.
Diverse Technological Platforms: Ace Therapeutics develops and customizes biomarker assays across a diverse range of technological platforms, adapting each to the specific requirements of IBD research. Our capabilities include the design and optimization of immunoassays, mass spectrometry protocols, flow cytometry panels, molecular diagnostic assays, and advanced histopathology or imaging workflows. Each platform is selected and configured to maximize sensitivity, specificity, and compatibility with the intended sample types and research objectives.
Immunoassays: We offer development and optimization of ELISA, chemiluminescent, and multiplex immunoassays for quantitative detection of cytokines, chemokines, and proteins in various biological matrices.
Mass Spectrometry: We utilize LC-MS/MS for high-sensitivity, quantitative analysis of proteins, peptides, and metabolites relevant to IBD research.
Flow Cytometry: Custom flow cytometry panels are designed for multiparametric analysis of immune cell populations and intracellular biomarkers, enabling detailed immune profiling.
Molecular Diagnostics: We provide nucleic acid-based assays, including quantitative PCR and transcriptome analysis, for detection and quantification of gene expression changes.
Histopathology And Imaging: Our services include immunohistochemistry, immunofluorescence, and digital image analysis for localization and quantification of biomarkers in tissue sections.
Rigorous Method Validation: All analytical methods undergo rigorous validation in accordance with established research guidelines. We assess performance characteristics such as sensitivity, specificity, linearity, accuracy, precision, and reproducibility. Comprehensive quality control measures—including the use of standards, controls, and replicate analyses—are implemented to ensure data reliability and integrity throughout the validation process.
Our quantitative analysis capabilities enable precise measurement of biomarker concentrations and expression levels in diverse sample types. We utilize advanced data processing and normalization techniques to ensure accurate interpretation, supporting robust comparison across experimental groups and time points in preclinical IBD studies.
Sample Analysis: We handle a wide range of sample types, including serum, plasma, tissue homogenates, cell lysates, and biological fluids relevant to IBD models. Each analysis follows standardized protocols for sample preparation, storage, and processing, with stringent quality assurance at every step. Our workflows are designed to minimize pre-analytical variability and maximize data consistency.
High Throughput Capabilities: Our high-throughput analytical platforms support multiplexed assays, enabling simultaneous measurement of multiple biomarkers from limited sample volumes. This approach increases efficiency, reduces reagent consumption, and conserves valuable preclinical samples, making it ideal for large-scale screening and longitudinal studies.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| C-X-C motif chemokine ligand 8 (CXCL8) | C-X-C motif chemokine ligand 8 (CXCL8), also known as interleukin-8 (IL-8), is a pro-inflammatory chemokine produced by various cell types, including macrophages, epithelial cells, and endothelial cells. CXCL8 primarily functions as a chemoattractant for neutrophils, guiding their migration to sites of infection or tissue injury. It exerts its effects by binding to the CXCR1 and CXCR2 receptors on target cells, leading to activation of intracellular signaling pathways that promote chemotaxis, degranulation, and respiratory burst in neutrophils. In addition to its role in innate immune responses, CXCL8 is involved in angiogenesis and has been implicated in the regulation of cell proliferation and survival in certain contexts. | CXCL8 has been studied as a biomarker in various inflammatory and infectious diseases, such as sepsis, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis, where elevated levels are associated with disease activity and severity. It is also investigated in oncology, as increased CXCL8 expression has been observed in several cancer types and may correlate with tumor progression, angiogenesis, and metastatic potential. Measurement of CXCL8 in biological fluids, such as serum, plasma, or bronchoalveolar lavage, is used in research settings to assess inflammatory status or monitor disease progression. |
| albumin (ALB) | Albumin (ALB) is the most abundant plasma protein in human blood, primarily synthesized by the liver. It plays a critical role in maintaining colloid osmotic (oncotic) pressure, which is essential for the proper distribution of body fluids between blood vessels and tissues. Albumin also serves as a carrier protein, binding and transporting a variety of endogenous and exogenous substances, including hormones, fatty acids, bilirubin, drugs, and metal ions. Additionally, albumin contributes to pH buffering and exhibits antioxidant properties by binding free radicals and reactive oxygen species. | Serum albumin concentration is widely used as a clinical biomarker for assessing nutritional status, liver function, and kidney function. Decreased albumin levels (hypoalbuminemia) are commonly observed in chronic liver diseases, nephrotic syndrome, malnutrition, inflammation, and acute or chronic illnesses. Conversely, increased levels (hyperalbuminemia) are less common and may be associated with dehydration. Albumin measurement is a standard component of liver and renal function panels and is utilized to monitor disease progression and response to therapy in various clinical settings. |
| forkhead box P3 (FOXP3) | Forkhead box P3 (FOXP3) is a transcription factor that plays a critical role in the development and function of regulatory T cells (Tregs), a subset of CD4+ T lymphocytes involved in maintaining immune homeostasis and self-tolerance. FOXP3 regulates the expression of genes necessary for the suppressive activity of Tregs and is considered a master regulator of their lineage commitment. Mutations in the FOXP3 gene are associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, highlighting its essential role in immune regulation. | FOXP3 is widely used as a biomarker for the identification and quantification of regulatory T cells in various tissues and peripheral blood. Its expression is assessed in contexts such as autoimmune diseases, transplantation, allergy, and cancer, where Treg frequency and function are of interest. In oncology, FOXP3+ Treg infiltration is often evaluated in tumor microenvironments to study immune suppression and potential impacts on prognosis. In addition, FOXP3 immunostaining is utilized in histopathological analyses to characterize immune cell populations. |
| interferon gamma (IFNG) | Interferon gamma (IFNG) is a cytokine produced primarily by activated T lymphocytes and natural killer (NK) cells. It plays a critical role in both innate and adaptive immunity. IFNG is a key activator of macrophages and is essential for the development of Th1-type immune responses. It enhances antigen presentation by upregulating major histocompatibility complex (MHC) class I and II molecules, stimulates the expression of various immunoregulatory genes, and promotes the elimination of intracellular pathogens such as viruses and certain bacteria. IFNG also modulates the proliferation and differentiation of immune cells and has anti-proliferative and immunomodulatory effects. | IFNG is widely used as a biomarker for cellular immune responses, particularly in the context of infectious diseases and immune-mediated disorders. Measurement of IFNG production, such as in interferon-gamma release assays (IGRAs), is applied to assess exposure to Mycobacterium tuberculosis. Elevated or dysregulated levels of IFNG have also been associated with autoimmune diseases, chronic inflammatory conditions, and monitoring of immunotherapy responses. Its quantification can provide insights into immune activation status and disease progression in various clinical and research settings. |
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced primarily by activated macrophages, as well as other cell types such as monocytes, dendritic cells, and epithelial cells. It is synthesized as an inactive precursor (pro-IL1B) and is cleaved by caspase-1 within the inflammasome complex to its active form. IL1B plays a central role in the regulation of immune and inflammatory responses, including the induction of fever, activation of lymphocytes, promotion of leukocyte infiltration, and modulation of cell proliferation, differentiation, and apoptosis. It also stimulates the production of other cytokines, chemokines, and adhesion molecules, thereby amplifying inflammatory signaling cascades. | IL1B is commonly measured in biological fluids such as serum, plasma, or synovial fluid to assess the presence and degree of inflammation. Elevated levels of IL1B have been associated with a variety of inflammatory and autoimmune conditions, including rheumatoid arthritis, sepsis, inflammatory bowel disease, and certain infectious diseases. Its quantification is used in research and clinical studies to monitor inflammatory activity, evaluate disease severity, and assess response to anti-inflammatory therapies. |
| interleukin 10 (IL10) | Interleukin 10 (IL10) is a cytokine produced by a variety of cell types, including T cells, B cells, macrophages, and dendritic cells. Its primary biological function is to limit and terminate inflammatory responses by inhibiting the synthesis of pro-inflammatory cytokines such as IFN-γ, IL-2, IL-3, TNF-α, and GM-CSF produced by activated macrophages and regulatory T cells. IL10 also suppresses antigen presentation by downregulating the expression of major histocompatibility complex (MHC) class II molecules and co-stimulatory molecules on antigen-presenting cells. Through these mechanisms, IL10 plays a crucial role in immune regulation, maintaining immune homeostasis, and preventing excessive tissue damage during immune responses. | IL10 is commonly measured in biological fluids such as blood, plasma, or serum to assess immune system activity and the extent of inflammation. Elevated IL10 levels have been observed in various clinical contexts, including infectious diseases, autoimmune disorders, and certain cancers. In infectious diseases, increased IL10 may reflect an anti-inflammatory response to limit tissue damage. In autoimmune conditions, altered IL10 levels can indicate dysregulation of immune tolerance. In oncology, IL10 concentrations have been studied in relation to tumor progression and immune evasion. Monitoring IL10 can provide information on disease activity, prognosis, and response to therapy in these settings. |
| interleukin 12B (IL12B) | Interleukin 12B (IL12B) encodes the p40 subunit, which combines with the p35 subunit to form the heterodimeric cytokine interleukin-12 (IL-12), and with the p19 subunit to form interleukin-23 (IL-23). IL-12 is produced primarily by antigen-presenting cells such as dendritic cells, macrophages, and B cells. It is a key regulator of cell-mediated immunity, promoting the differentiation of naive T cells into Th1 cells and stimulating the production of interferon-gamma (IFN-γ) by T cells and natural killer (NK) cells. IL-23, which also contains the IL12B-encoded p40 subunit, is involved in the expansion and maintenance of Th17 cells and contributes to inflammatory responses. Thus, IL12B plays a central role in modulating immune responses, particularly in the context of inflammation and host defense against intracellular pathogens. | IL12B expression levels and circulating protein concentrations have been studied as biomarkers in various immune-mediated and inflammatory conditions. Elevated IL12B or its p40 subunit has been associated with autoimmune diseases such as psoriasis, Crohn's disease, and rheumatoid arthritis, reflecting its involvement in disease pathogenesis and immune activation. Measurement of IL12B or its encoded protein products in blood or tissue samples has been used in research to assess disease activity, monitor therapeutic responses, and explore their roles in distinguishing between different immune-related disorders. |
| interleukin 17A (IL17A) | Interleukin 17A (IL17A) is a pro-inflammatory cytokine produced primarily by a subset of T helper cells known as Th17 cells, as well as other immune cells including γδ T cells, natural killer cells, and innate lymphoid cells. IL17A plays a central role in host defense against extracellular bacteria and fungi by promoting the recruitment and activation of neutrophils. It stimulates the production of chemokines, cytokines, and antimicrobial peptides by various cell types, such as epithelial cells, endothelial cells, and fibroblasts. Through these actions, IL17A contributes to the amplification of inflammatory responses and is involved in the maintenance of mucosal barrier integrity. | IL17A has been investigated as a biomarker in various immune-mediated and inflammatory conditions. Elevated levels of IL17A in serum, plasma, or tissue samples have been associated with diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Measurement of IL17A can provide information on the presence and extent of inflammatory activity, and may be used in research settings to monitor disease progression or response to therapy. Its expression patterns have also been studied in the context of infection and cancer-related inflammation. |
| interleukin 6 (IL6) | Interleukin 6 (IL6) is a multifunctional cytokine produced by various cell types, including T cells, B cells, macrophages, fibroblasts, and endothelial cells. It plays a central role in the regulation of immune responses, acute-phase reactions, hematopoiesis, and inflammation. IL6 mediates its effects through binding to the IL6 receptor complex, which activates intracellular signaling pathways such as the JAK/STAT pathway. It is involved in the stimulation of B cell differentiation, promotion of T cell proliferation, induction of hepatic acute-phase protein synthesis, and regulation of metabolic, regenerative, and neural processes. Dysregulation of IL6 production is associated with chronic inflammation and has been implicated in the pathogenesis of various diseases, including autoimmune disorders and certain cancers. | IL6 is measured in biological fluids such as serum, plasma, or cerebrospinal fluid to assess inflammatory status. Elevated IL6 concentrations are associated with a range of inflammatory and infectious conditions, including sepsis, rheumatoid arthritis, and COVID-19. It is used to monitor disease activity, evaluate prognosis, and assess response to therapy in certain clinical contexts. IL6 levels may also aid in distinguishing between inflammatory and non-inflammatory states in various diseases. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF), also known as TNF-alpha, is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as other immune and non-immune cells. TNF plays a central role in the regulation of immune responses, inflammation, and apoptosis. It exerts its effects by binding to two distinct cell surface receptors, TNFR1 and TNFR2, initiating intracellular signaling cascades that can result in cell survival, differentiation, or programmed cell death. TNF is involved in the pathogenesis of various physiological and pathological processes, including host defense against infections, fever induction, and the modulation of other cytokines. Its dysregulation has been associated with chronic inflammatory and autoimmune conditions. | TNF is commonly measured in biological fluids, such as serum and plasma, to assess the presence and degree of inflammation. Its levels are frequently evaluated in clinical and research settings to monitor inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and sepsis. TNF concentrations can serve as an indicator of disease activity or response to anti-TNF therapies. It is also used in studies investigating the inflammatory response to infections, trauma, and other immune-mediated conditions. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services provide comprehensive, exploratory support for preclinical Inflammatory Bowel Disease therapeutic development. We offer advanced analytical platforms and scientific expertise to facilitate the discovery and characterization of research biomarkers. Please note that all biomarkers discussed are research targets only; we do not claim any biomarker as validated or mandatory for any application. Our services are strictly limited to preclinical research, and all findings are intended for scientific exploration rather than clinical use. Ace Therapeutics maintains an objective, research-focused approach to biomarker analysis.
We invite you to connect with Ace Therapeutics to discuss collaborative opportunities in exploratory biomarker research for Inflammatory Bowel Disease. Our team is dedicated to scientific knowledge exchange and advancing preclinical research through objective, data-driven collaboration.
Make Order
Experimental Scheme
Implementation
Conclusion
